Xencor (NASDAQ:XNCR) Posts Earnings Results, Beats Expectations By $0.27 EPS

Xencor (NASDAQ:XNCR) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27, Briefing.com reports. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The firm’s quarterly revenue was down 81.9% compared to the same quarter last year. During the same period last year, the company posted ($0.40) EPS.

Xencor Trading Up 2.4 %

Shares of NASDAQ:XNCR traded up $0.54 on Thursday, hitting $23.22. 370,486 shares of the company’s stock were exchanged, compared to its average volume of 596,248. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92. The business’s 50 day simple moving average is $20.21 and its two-hundred day simple moving average is $20.21. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -7.88 and a beta of 0.66. Xencor has a 12 month low of $15.31 and a 12 month high of $26.84.

Wall Street Analyst Weigh In

XNCR has been the subject of a number of research reports. Wedbush restated an “outperform” rating and issued a $38.00 price target on shares of Xencor in a report on Thursday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Xencor in a research report on Tuesday, August 6th. JPMorgan Chase & Co. lifted their price objective on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Royal Bank of Canada boosted their price objective on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Xencor has a consensus rating of “Moderate Buy” and an average target price of $35.33.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.